Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis: Anthony Sireci, Maria Arcila

Biocartis has appointed a new medical advisory board, effective Aug. 28. The first two members are Anthony "Nino" Sireci and Maria Arcila. Additional members will join in the coming weeks.

Sireci, a board-certified clinical pathologist and a practicing molecular pathologist, currently serves as senior VP of diagnostics development at Loxo Oncology at Lilly. Prior to joining Loxo, Sireci was a professor of pathology at Columbia University and medical director in the Laboratory of Personalized Genomic Medicine at Columbia Medical Center. He is a member of the pathology coding caucus in the College of American Pathologists and the molecular pathology advisory group in the American Medical Association.

Arcila has served as director of the molecular pathology laboratory at Memorial Sloan Kettering Cancer Center and is currently the deputy chief of the molecular diagnostic service. Her research highlights therapeutic and prognostic molecular markers in solid tumors and hematologic malignancies and focuses on the expansion, validation, and implementation of clinical tests to optimize precision medicine.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.